Pages that link to "Q34740986"

The following pages link to NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes (Q34740986):

Displaying 26 items.

• Integrating mutation variant allele frequency into clinical practice in myeloid malignancies (Q26748915) (← links)
• Clinical and genetic predictors of prognosis in myelodysplastic syndromes (Q33695906) (← links)
• p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). (Q33695954) (← links)
• The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia (Q33796552) (← links)
• The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure (Q33829778) (← links)
• TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients (Q34398397) (← links)
• Single-tube, highly parallel mutation enrichment in cancer gene panels by use of temperature-tolerant COLD-PCR. (Q34799278) (← links)
• CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse (Q36608689) (← links)
• Elimination of unaltered DNA in mixed clinical samples via nuclease-assisted minor-allele enrichment (Q37401069) (← links)
• DMSO Increases Mutation Scanning Detection Sensitivity of High-Resolution Melting in Clinical Samples (Q37503539) (← links)
• Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing (Q38662892) (← links)
• Emerging biological therapies for the treatment of myelodysplastic syndromes (Q38834981) (← links)
• COLD-PCR Technologies in the Area of Personalized Medicine: Methodology and Applications. (Q39094514) (← links)
• p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia (Q39213887) (← links)
• Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies (Q40483796) (← links)
• Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia (Q41183059) (← links)
• Identify latent chromosomal aberrations relevant to myelodysplastic syndromes (Q41606092) (← links)
• Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation (Q42158416) (← links)
• Lack of splice factor and cohesin complex mutations in pediatric myelodysplastic syndrome (Q42335811) (← links)
• Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. (Q48240827) (← links)
• Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes (Q49533848) (← links)
• Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing (Q49817248) (← links)
• Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies (Q57053765) (← links)
• Enhanced detection of microsatellite instability using pre-PCR elimination of wild-type DNA homo-polymers in tissue and liquid biopsies (Q88319839) (← links)
• A nuclease-polymerase chain reaction enables amplification of probes used for capture-based DNA target enrichment (Q90621936) (← links)
• TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (Q91011066) (← links)